Aurobindo Pharma Other Announcement
Aurobindo Pharma's subsidiary, CuraTeQ Biologics, announced positive Phase 3 results for its Omalizumab biosimilar (BP11). The study met all primary endpoints for efficacy and safety, showing equivalence to Xolair. The company plans to file for EMA and FDA regulatory approvals by the end of Q2 2026.
- Execution
- Q2 2026